Callahan R. et al. revealed that imatinib mesylate was able to induce complete regression of mammary tumor and restore lobuloalveolar development and lactation by inhibiting Notch4 and Myc signaling, which result also support the idea of therapeutic potential of imatinib mesylate, other than CML and GIST [87]. This evidence concerns the gene MYC and chronic myelogenous leukemia, BCR-ABL1 positive.